List view / Grid view
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s…
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
The trial will evaluate the safety and efficacy of the…
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
The Phase II clinical trial to study NVX-CoV2373, the Novavax…
The Phase II clinical trial to study NVX-CoV2373, the Novavax COVID-19 vaccine candidate, has enrolled its first patient.
A Phase I trial conducted by Novavax to test NVX‑CoV2373,…
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
